Mankind Pharma Ltd

NSE
MANKIND •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Mankind Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
73.43% Gain from 52W Low
11.4
TTM PE Ratio
High in industry
49.8
Price to Book Ratio
High in industry
11.3
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is slightly more than 1
1.1
RSI
RSI is mid-range
50.9
MFI
MFI Overbought
73

Mankind Pharma Ltd Key Financials

*All values are in ₹ Cr.

Mankind Pharma Ltd shareholding Pattern

Promoter
76.5%
Foreign Institutions
6.7%
Mutual Funds
7.6%
Domestic Institutions
9.8%
Public
7%

Mankind Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
10
Bearish Moving Averages
6
5Day EMA
2,181.70
10Day EMA
2,182.20
12Day EMA
2,179.10
20Day EMA
2,162.90
26Day EMA
2,149.40
50Day EMA
2,094.00
100Day EMA
1,994.60
200Day EMA
1,822.90
Delivery & Volume
Resistance & Support
2,172.35
Pivot
Resistance
First Resistance
2,196.70
Second Resistance
2,239.35
Third Resistance
2,263.70
Support
First Support
2,129.70
Second support
2,105.35
Third Support
2,062.70
Relative Strength Index
50.94
Money Flow Index
73.05
MACD
29.64
MACD Signal
34.17
Average True Range
69.46
Average Directional Index
21.62
Rate of Change (21)
4.53
Rate of Change (125)
17.85

Mankind Pharma Ltd Company background

Founded in: 1991
Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name Mankind Pharma Private Limited, by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to Mankind Pharma Limited and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including antiinfectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind tablets and Glimestar tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops and Tobastar Eye Drops. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineralsupplements and antiacne preparations categories. It entered into the business of animal healthcare segment and launched Bandykind and Ceftiforce. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009. It launched the brand, Preganews into the consumer healthcare segment in year, 2010. In 2012, it set up their first RD centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh. In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company.In 2017, a new manufacturing facility got established in Sikkim.In 2019, the Company entered into female infertility business segment and launched Dydroboon tablets.In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched Cilaheart tablets and Statpure tablets in the market. It launched Zukanorm tablets for diabetes pharmaceuticals segment.Another new subsidiary, Mankind Pharma FZLLC in Dubai, UAE got incorporated during the year 2021. It launched Mlife tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of TrugabaNT tablets and PrebrisMNT tablets.In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of Pangraf Capsules and Mycept tablets. It entered into the business of oncology segment with the launch of injection Pacliall. It acquired Daffy and Combihale brands from Dr. Reddys Laboratories. The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other overthecounter products, as of March 31, 2022.The Company is planning to raise capital from Public by issuing 40,058,844 Equity Shares through Offer for Sale.
Read More

Mankind Pharma Ltd FAQs

Mankind Pharma Ltd shares are currently priced at 2154.05 on NSE and 2153.45 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Mankind Pharma Ltd [MANKIND] share was 0. The Mankind Pharma Ltd [MANKIND] share hit a 1-year low of Rs. 1242 and a 1-year high of Rs. 2297.4.

The market cap of Mankind Pharma Ltd is Rs. 86288.75 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Mankind Pharma Ltd is 52.27 as of 2/22/2024 12:00:00 AM.

The PB ratios of Mankind Pharma Ltd is 9.94 as of 2/22/2024 12:00:00 AM

The Mutual Fund Shareholding was 7.55% at the end of 2/22/2024 12:00:00 AM.

You can easily buy Mankind Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage